Why the study?
Immune checkpoint inhibitors and tyrosine kinase inhibitors are effective cancer therapies but can cause cardiotoxicity side effects.
Case Report (n=1)
No
This case highlights the potential for simultaneous severe cardiotoxicities, including axitinib-induced thrombotic STEMI and pembrolizumab-induced myocarditis, which can be successfully managed with PCI and high-dose steroids.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Fratti et al. (2023) conducted a case report in Renal cell carcinoma (n=1). Pembrolizumab and Axitinib was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: